Managing Infections and Antibody Deficiency
At a Glance
For NFKB1-related immune dysregulation, infection care may include immunoglobulin replacement, preventive antibiotics or antivirals, and individualized vaccine decisions. The aim is to reduce serious infections and prevent lasting lung damage, with treatment adjusted over time.
Managing NFKB1-related immune dysregulation often starts with addressing the most visible challenge: a frequent and recurring cycle of infections. Because your immune system has difficulty producing effective antibodies and maintaining a strong defense, your medical team will likely focus on “filling the gap” in your immune protection [1][2].
Immunoglobulin Replacement Therapy (IgRT)
For many patients with NFKB1 variants, a primary treatment consideration is Immunoglobulin Replacement Therapy (IgRT). This therapy provides you with antibodies (IgG) collected from healthy donors, giving your body the “tools” it needs to fight bacteria and viruses [3].
- When It’s Used: Doctors typically consider IgRT if you have clinically significant infection susceptibility alongside very low IgG levels and/or poor responses to vaccines [2][4].
- The Goal: The main goal of IgRT is not to make your blood laboratory numbers “perfect,” but to reduce the frequency and severity of your infections and prevent long-term damage, like lung scarring (bronchiectasis) [4][5].
- Delivery Methods:
- IVIG (Intravenous): Given through a vein, usually in a clinic or hospital every 3 to 4 weeks [6].
- SCIG (Subcutaneous): Infused under the skin, often at home, once or twice a week. Many patients prefer this “slow and steady” approach because it can lead to more consistent antibody levels and fewer systemic side effects [7][8].
It is common to feel fatigued the day of or the day after an infusion; communicate with your team about any side effects or infusion reactions.
Prophylactic (Preventive) Medications
In some cases, IgRT alone isn’t enough to stop all infections. Your doctor might discuss “prophylactic” medications—preventive antibiotics or antivirals to keep germs from gaining a foothold [9].
- Antibiotics: Common choices discussed include medications like azithromycin or trimethoprim-sulfamethoxazole [10][11]. However, selection heavily depends on your specific infection pattern, cultures, presence of bronchiectasis, local resistance, and allergy profile. These are individualized specialist decisions.
- Antivirals: Routine EBV antiviral prophylaxis is not a standard requirement. However, if your lab work shows that your T-cells are significantly affected, or if you have specific indications (like recurrent herpes), your doctor may prescribe a preventive antiviral [12][11].
Navigating Vaccinations
Vaccines are a complex topic for people with NFKB1 variants. Because your immune system doesn’t “remember” germs well, your response to vaccines may be weak or absent [13][14]. Also, IgRT provides donor antibodies that can interfere with certain vaccine responses and interpretations.
- Non-Live Vaccines: Vaccines that do not contain live virus—such as mRNA COVID-19 vaccines, the inactivated flu shot, and pneumococcal vaccines—are generally considered safe [15][16]. While they may not provide “full” protection, they can often prime your T-cells to offer some level of defense [17][18].
- Live-Attenuated Vaccines: These vaccines (like MMR, varicella, oral rotavirus, or the nasal flu spray) contain a weakened live virus. Having NFKB1 does not automatically make all live vaccines unsafe; decisions must be highly individualized based on your T-cell number and function, age, and medication status [19][15].
- Household Strategy: To protect you, doctors often recommend that everyone in your household stay up-to-date on vaccines, while employing specific precautions for household members receiving live vaccines [16].
Your infection management plan is not static. As you age, or as your immune system changes, your doctor will adjust your IgRT dose or your preventive medications to ensure you have the best possible protection [20][8]. Have an explicit action plan with your doctor regarding when to call for fevers and when to request chest imaging or cultures.
Common questions in this guide
When might immunoglobulin replacement therapy be used for NFKB1-related immune dysregulation?
What is the difference between IVIG and SCIG?
Are vaccines safe for people with NFKB1-related immune dysregulation?
Can preventive antibiotics or antivirals reduce infections?
How often should infection treatment be reassessed?
Get notified when new evidence is published on NFKB1-related immune dysregulation.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (20)
- 1
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations.
Lorenzini T, Fliegauf M, Klammer N, et al.
The Journal of allergy and clinical immunology 2020; (146(4)):901-911 doi:10.1016/j.jaci.2019.11.051.
PMID: 32278790 - 2
When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
Jolles S, Chapel H, Litzman J
Clinical and experimental immunology 2017; (188(3)):333-341 doi:10.1111/cei.12915.
PMID: 28000208 - 3
Common Variable Immunodeficiency Disorders: A perspective from New Zealand.
Ameratunga R, J Longhurst H, Lehnert K, et al.
Clinical reviews in allergy & immunology 2025; (68(1)):105 doi:10.1007/s12016-025-09099-2.
PMID: 41324804 - 4
Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia.
Brent J, Guzman D, Bangs C, et al.
Clinical and experimental immunology 2016; (184(1)):73-82 doi:10.1111/cei.12748.
PMID: 26646609 - 5
Limitations in the clinical utility of vaccine challenge responses in the evaluation of primary antibody deficiency including Common Variable Immunodeficiency Disorders.
Ameratunga R, Longhurst H, Leung E, et al.
Clinical immunology (Orlando, Fla.) 2024; (266()):110320 doi:10.1016/j.clim.2024.110320.
PMID: 39025346 - 6
Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S, Kristofek L, Bolgar W, et al.
Journal of managed care & specialty pharmacy 2017; (23(4)):400-406 doi:10.18553/jmcp.2017.23.4.400.
PMID: 28345437 - 7
CVID Associated with Systemic Amyloidosis.
Esenboga S, Çagdas Ayvaz D, Saglam Ayhan A, et al.
Case reports in immunology 2015; (2015()):879179 doi:10.1155/2015/879179.
PMID: 26346511 - 8
Common Variable Immunodeficiency.
Remiker A, Bolling K, Verbsky J
The Medical clinics of North America 2024; (108(1)):107-121 doi:10.1016/j.mcna.2023.06.012.
PMID: 37951645 - 9
Specific Antibody Deficiency: Controversies in Diagnosis and Management.
Perez E, Bonilla FA, Orange JS, Ballow M
Frontiers in immunology 2017; (8()):586 doi:10.3389/fimmu.2017.00586.
PMID: 28588580 - 10
Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency.
Tiotiu A, Salvator H, Jaussaud R, et al.
Allergology international : official journal of the Japanese Society of Allergology 2020; (69(2)):215-222 doi:10.1016/j.alit.2019.10.011.
PMID: 31812484 - 11
[Prophylactic and therapeutic management of increased susceptibility to infection in patients with immunodeficiency].
Hanitsch LG
Der Internist 2022; (63(5)):484-492 doi:10.1007/s00108-022-01326-8.
PMID: 35412057 - 12
Human NF-κB1 Haploinsufficiency and Epstein-Barr Virus-Induced Disease-Molecular Mechanisms and Consequences.
Hoeger B, Serwas NK, Boztug K
Frontiers in immunology 2017; (8()):1978 doi:10.3389/fimmu.2017.01978.
PMID: 29403474 - 13
Common variable immunodeficiency due to a novel variant in NFKB1 with a neonatal presentation of parechovirus meningitis and sepsis-like illness.
Szczawińska-Popłonyk A, Popłonyk N, Bernat-Sitarz K, et al.
Allergologia et immunopathologia 2025; (53(3)):31-40 doi:10.15586/aei.v53i3.1307.
PMID: 40342112 - 14
Common Variable Immunodeficiency and Neurodevelopmental Delay Due to a 13Mb Deletion on Chromosome 4 Including the NFKB1 Gene: A Case Report.
Franco-Jarava C, Valenzuela I, Riviere JG, et al.
Frontiers in immunology 2022; (13()):897975 doi:10.3389/fimmu.2022.897975.
PMID: 35784294 - 15
Vaccination in Primary Immunodeficiency Disorders.
Sobh A, Bonilla FA
The journal of allergy and clinical immunology. In practice 2016; (4(6)):1066-1075 doi:10.1016/j.jaip.2016.09.012.
PMID: 27836056 - 16
Influenza Vaccination in Patients with Common Variable Immunodeficiency (CVID).
Mieves JF, Wittke K, Freitag H, et al.
Current allergy and asthma reports 2017; (17(11)):78 doi:10.1007/s11882-017-0749-3.
PMID: 28983790 - 17
Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
Hanitsch LG, Löbel M, Mieves JF, et al.
Vaccine 2016; (34(21)):2417-2423 doi:10.1016/j.vaccine.2016.03.091.
PMID: 27055021 - 18
Antibody and T-cell responses to coronavirus disease 2019 vaccination in common variable immunodeficiency and specific antibody deficiency.
Rosenthal JA, Papa MP, Sanz M, et al.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2023; (130(6)):743-751.e3 doi:10.1016/j.anai.2023.01.025.
PMID: 36736722 - 19
Vaccination in PADs.
Milito C, Soccodato V, Collalti G, et al.
Vaccines 2021; (9(6)) doi:10.3390/vaccines9060626.
PMID: 34207916 - 20
Vulnerability to Meningococcal Disease in Immunodeficiency Due to a Novel Pathogenic Missense Variant in NFKB1.
Anim M, Sogkas G, Schmidt G, et al.
Frontiers in immunology 2021; (12()):767188 doi:10.3389/fimmu.2021.767188.
PMID: 35003082
This page is for informational purposes only and does not constitute medical advice. An immunology specialist should tailor IgRT, preventive medicines, and vaccine decisions to your immune tests and infection history.